Ovarian Cancer
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Ovarian Cancer is a highly competitive landscape with 701 programs across 220 companies. The most active players are Sun Pharma Advanced Research Company Limited, Daewoong Pharmaceutical Co. LTD., Celldex Therapeutics. 24 therapies are approved with 109 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Sun Pharma Advanced Research Company Limited
4 programs
Daewoong Pharmaceutical Co. LTD.
2 programs
Celldex Therapeutics
2 programs
Azaya Therapeutics, Inc.
2 programs
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
2 programs
TetraLogic Pharmaceuticals
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
84%
Small molecule
625 of 740 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 740 classified programs, each share of the total. Modality classified for 99% of 837 pipeline programs.
Analysis
Trial Status
1,015
clinical trials
Clinical Trials
Trial Activity
1015 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)